Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Marija Balic


Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242


M. Balic1, C. Suppan2, I. Brcic3, V. Tiran2, D.H. Mueller2, F. Posch4, P. Ulz5, E. Heitzer5, N. Dandachi6

Author affiliations

  • 1 Department Of Internal Medicine, LKH-Univ. Klinikum Graz, 8036 - Graz/AT
  • 2 Division Of Oncology, Department Of Internal Medicine, Medical University Graz, 8010 - Graz/AT
  • 3 Diagnostic And Research Institute Of Pathology, Medical University Graz, 8010 - Graz/AT
  • 4 Division Of Oncology, LKH-Univ.Klinikum Graz - Universitätsklinik für Innere Medizin, 8036 - Graz/AT
  • 5 Institute Of Human Genetics, Medical University Graz, 8010 - Graz/AT
  • 6 1division Of Oncology; Department Of Internal Medicine, Medical University Graz, 8010 - Graz/AT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5640


The aim of this study was to assess the prognostic and predictive value of an untargeted assessment of tumor fractions in the plasma of metastatic breast cancer patients and to compare circulating tumor DNA (ctDNA) with circulating tumor cells (CTC) and conventional tumor markers.


Patients and methods: 29 patients with metastatic breast cancer were included in this single-institution observational cohort study. Blood samples were obtained at first diagnosis of metastases, during several lines of treatment, and/or at every further moment of progression/development of new metastases. We assessed tumor fractions in plasma using an untargeted mFAST-SeqS method. CTCs were captured using a sized-based microfilter and identified as nucleated, cytokeratin positive/CD45 negative cells. Resulting ctDNA z-scores were compared to tumor fractions established with the recently published ichorCNA algorithm and associated with the clinical outcome.


We observed a close correlation between mFAST-SeqS z-scores and ichorCNA ctDNA quantifications. Patients with mFAST-SeqS z-scores above three (34.5%) showed significantly worse overall (p = 0.014) and progression-free survival (p = 0.018) compared to patients with lower values. Elevated z-score values were clearly associated with radiological proven progression. In contrast, baseline CTC count, CEA, and CA15-5 had no prognostic impact on the outcome of patients in the analyzed cohort.


This proof of principle study demonstrates the prognostic impact of ctDNA levels detected with mFAST-SeqS as a very fast and cost-effective means to assess the ctDNA fraction without prior knowledge of the genetic landscape of the tumor. Furthermore, mFAST-SeqS-based ctDNA levels provided an early means of measuring treatment response.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Krebshilfe Steiermark.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.